{"organizations": [], "uuid": "dc40b59a4e6294de876d9f707b64e4740a5c874b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biohaven-announces-license-agreeme/brief-biohaven-announces-license-agreement-with-catalent-for-zydis-odt-with-small-molecule-cgrp-receptor-antagonists-idUSFWN1QB06R", "country": "US", "domain_rank": 408, "title": "BRIEF-Biohaven Announces License Agreement With Catalent For Zydis ODT With Small Molecule Cgrp Receptor Antagonists", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T10:06:00.000+02:00", "replies_count": 0, "uuid": "dc40b59a4e6294de876d9f707b64e4740a5c874b"}, "author": "", "url": "https://www.reuters.com/article/brief-biohaven-announces-license-agreeme/brief-biohaven-announces-license-agreement-with-catalent-for-zydis-odt-with-small-molecule-cgrp-receptor-antagonists-idUSFWN1QB06R", "ord_in_thread": 0, "title": "BRIEF-Biohaven Announces License Agreement With Catalent For Zydis ODT With Small Molecule Cgrp Receptor Antagonists", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.k.", "sentiment": "none"}], "organizations": [{"name": "bengaluru newsroom", "sentiment": "none"}, {"name": "reuters) - biohaven pharmaceutical holding company ltd", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "small molecule cgrp receptor antagonists reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 21, 2018 / 8:09 AM / Updated 9 minutes ago BRIEF-Biohaven Announces License Agreement With Catalent For Zydis ODT With Small Molecule Cgrp Receptor Antagonists Reuters Staff 1 Min Read Feb 21 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd: * BIOHAVEN ANNOUNCES EXCLUSIVE LICENSE WITH CATALENT FOR ZYDIS® ORALLY DISSOLVING TABLET WITH SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS * ENTERED LICENSE AGREEMENT CATALENT U.K. SWINDON ZYDIS LTD TO PROVIDE CATALENT‘S ZYDIS ODT FAST-DISSOLVING FORMULATION * AGREEMENT FOR DEVELOPMENT OF BIOHAVEN‘S LEAD CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST PRODUCT CANDIDATE, RIMEGEPANT * AGREEMENT ALSO PROVIDES EXCLUSIVE RIGHTS FOR DEVELOPING SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS WITH ZYDIS ODT TECHNOLOGY Source text for Eikon: Further company coverage: (Bengaluru Newsroom)", "external_links": [], "published": "2018-02-21T10:06:00.000+02:00", "crawled": "2018-02-21T10:22:59.054+02:00", "highlightTitle": ""}